Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.
about
Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signallingAt the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of boneCytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.Frequent deregulations in the hedgehog signaling network and cross-talks with the epidermal growth factor receptor pathway involved in cancer progression and targeted therapies.Matriptase is involved in ErbB-2-induced prostate cancer cell invasionLentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cellsErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cellsRecent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies.Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistanceTendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.Epidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transitionEpithelial-mesenchymal transition in prostate cancer and the potential role of kallikrein serine proteases.Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas.Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomyThe ERBB3 receptor in cancer and cancer gene therapyRAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.Overexpression of USP39 predicts poor prognosis and promotes tumorigenesis of prostate cancer via promoting EGFR mRNA maturation and transcription elongation.Molecular mechanisms involving prostate cancer racial disparity.Pathogenesis of prostate cancer and hormone refractory prostate cancer.Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.Gαs protein expression is an independent predictor of recurrence in prostate cancerPotential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors.Androgen action and metabolism in prostate cancer.The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.Profiling serum HER-2/NEU in prostate cancer.Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression.High-Throughput Screen for Inhibitors of Androgen Receptor-RUNX2 Transcriptional Regulation in Prostate Cancer.SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro.EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma.ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cells.Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin.Nuclear HER3 is associated with favorable overall survival in uveal melanoma.Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
P2860
Q24650935-88B46EF4-C2A7-440B-8991-60E3A8161FB7Q26866067-674C3B6D-AF20-4A8F-BCED-0AC4607800FDQ33533700-82ECB87A-B42E-49F3-88A5-B88972784C82Q33653836-31CAE30B-4048-41BF-A21D-4A303F4968D3Q34244929-0D7C59CD-AAA6-416E-8801-1C66F83FF86AQ34358331-2FBBCB06-6BEB-470C-B1AA-7F74449E0F6AQ34976249-F19E21F5-B95F-4391-B0D6-C53F1F28DA44Q36025400-7D81478A-114C-40A3-B833-41E14A143270Q36048017-57574D8E-6C89-418B-9F2A-3296D995C654Q36272854-432A62F4-E26B-4610-92CA-E67A1C6EF6D0Q36282200-DDB4B00E-2E21-48C9-8C47-310127789C01Q36475900-08A8834A-CB2A-4FE2-9BB4-D5C904721139Q36543668-EC4B1AA2-7874-4946-BAC3-E9A573A3B24BQ36857803-15090696-F9B2-4926-9948-D01685F6D552Q36860976-6C938556-06AB-4CDD-8A32-2384DF419A00Q37091691-611F7021-46CB-4A44-8EBD-5419DFD650E1Q37120344-459EFAAE-C540-41D6-86DC-A612457537F5Q37135372-9BB026CB-FFA8-4786-83D2-A376CA54646AQ37149065-36D12E57-CF8C-4ABB-BCE1-7FB5C80883A8Q37225467-8E20A771-DD02-4CD5-9E08-02797E976DC7Q37418937-CA4216BF-184B-4202-B63F-617725A729CDQ37579070-4C222380-870E-4F98-BA1A-F628AF5C92EDQ37627154-BEDEE5FD-3F5F-477F-9381-DB77D444533FQ37706058-B0A94EFF-0CDE-457D-ADF8-853E09038955Q37974158-D1E10AA0-FDE8-4635-8FBC-88AABC440065Q37997571-CA2AD35D-F0FC-4707-927C-F05EA5D8C482Q38063121-5C7667D6-4800-450A-A36B-49F25F1B339AQ38112122-65172734-DFB4-42BF-BC32-F39A4D1F4C6CQ38174595-8D82B644-4AC7-4742-A6EC-D7625E1548BDQ38321512-FD926031-9969-4491-8EAE-B2F97E324335Q38750494-8BECB49A-F1B8-4B21-97FB-BC351DED8C4BQ39115039-00BD807A-615B-4C14-9FD3-5461653CE40DQ39139802-B453607F-84DB-4064-9843-EB8EF7F735FEQ39215370-BA5D5F1C-C831-42B7-B260-EABB029F7E42Q39471103-39691041-1E91-4990-BFDB-7D9A9DC7C51DQ39527913-5FDA311B-502D-4A4D-AB46-CB7D37769575Q39560158-22782099-AF0A-4B29-B015-F028B5A774C0Q39974009-43447573-BED5-4D33-AEB8-F136EA401749Q39986043-088ACCA2-3E3A-4796-B0AB-23BA9B5434B1Q39998599-7C9FF5C3-64FA-492F-8529-49E1FA832166
P2860
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Expression of the epidermal gr ...... during androgen-independence.
@ast
Expression of the epidermal gr ...... during androgen-independence.
@en
type
label
Expression of the epidermal gr ...... during androgen-independence.
@ast
Expression of the epidermal gr ...... during androgen-independence.
@en
prefLabel
Expression of the epidermal gr ...... during androgen-independence.
@ast
Expression of the epidermal gr ...... during androgen-independence.
@en
P2093
P2860
P356
P1476
Expression of the epidermal gr ...... during androgen-independence.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601536
P407
P577
2004-01-01T00:00:00Z